The Landscape of CEACAM5 Expression by Immunohistochemistry in NSCLC
Our data revealed that 18% of routinely diagnosed clinical NSCLC samples had high CEACAM5 expression by immunohistochemistry, and its expression was not associated with oncogenic driver mutations or patient prognosis in a predominantly early stage NSCLC cohort.
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- King Hussein Medical Center (JO)
- King Abdulaziz Medical City (SA)
- Princess Margaret Cancer Centre (CA)
- Shanghai Pulmonary Hospital (CN)
- National Guard Health Affairs (SA)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100943
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00